PROGRESS AND ROYALTY REPORTS. 8.1 For the period beginning [date] LICENSEE will submit to REGENTS a semi-annual progress report covering LICENSEE's activities related to the development and testing of all LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHOD and the obtaining of necessary governmental approvals, if any, for marketing in the United States. These progress reports will be made for all development activities until the first SALE occurs in the United States.
Appears in 7 contracts
Samples: Exclusive License Agreement With Equity, Exclusive License Agreement Without Equity, Exclusive License Agreement
PROGRESS AND ROYALTY REPORTS. 8.1 For the period beginning [date] LICENSEE will submit to REGENTS a semi-semi- annual progress report covering LICENSEE's activities related to the development and testing of all LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHOD and the obtaining of necessary governmental approvals, if any, for marketing in the United States. These progress reports will be made for all development activities until the first SALE occurs in the United States.
Appears in 4 contracts
Samples: Exclusive License Agreement With Equity, Exclusive License Agreement, Exclusive License Agreement With Equity
PROGRESS AND ROYALTY REPORTS. 8.1 For the each [***] period beginning [date] July 1, 2014, LICENSEE will submit to REGENTS a semi-annual [***] progress report covering LICENSEE's ’s activities related to the development and testing of all LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHOD METHODS and the obtaining of necessary governmental approvals, if any, for marketing in the United States. These progress reports will be made for all development activities until the first SALE occurs in the United States.
Appears in 4 contracts
Samples: Exclusive License and Bailment Agreement (4D Molecular Therapeutics Inc.), Exclusive License and Bailment Agreement (4D Molecular Therapeutics Inc.), Exclusive License and Bailment Agreement (4D Molecular Therapeutics Inc.)
PROGRESS AND ROYALTY REPORTS. 8.1 8.1. For the period beginning [date] January 1st 2007, LICENSEE will submit to REGENTS a semi-annual progress report covering LICENSEE's ’s activities related to the development and testing of all LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHOD and the obtaining of necessary governmental approvals, if any, for marketing in the United States. These progress reports will be made for all development activities until the first SALE occurs in the United States.
Appears in 4 contracts
Samples: Genocea Biosciences, Inc., Genocea Biosciences, Inc., Genocea Biosciences, Inc.
PROGRESS AND ROYALTY REPORTS. 8.1 7.1 For the period beginning [insert date] ], LICENSEE will submit to REGENTS a semi-semi- annual progress report covering LICENSEE's activities related to the development and testing of all LICENSED PRODUCTS., LICENSED SERVICES and LICENSED METHOD and the obtaining of necessary the governmental approvals, if any, for marketing in the United States. These progress reports will be made for all development activities until the first SALE occurs in the United States.
Appears in 2 contracts
Samples: Non Exclusive License Agreement, Non Exclusive License1
PROGRESS AND ROYALTY REPORTS. 8.1 7.1 For the period beginning [date] ], LICENSEE will submit to REGENTS a semi-annual progress report covering LICENSEE's activities related to the development and testing of all LICENSED PRODUCTS., LICENSED SERVICES and LICENSED METHOD and the obtaining of necessary the governmental approvals, if any, for marketing in the United States. These progress reports will be made for all development activities until the first SALE occurs in the United States.
Appears in 1 contract
Samples: Nonexclusive License*
PROGRESS AND ROYALTY REPORTS. 8.1 For the period beginning [date] January 2010 LICENSEE will submit to REGENTS a semi-annual progress report covering LICENSEE's ’s activities related to the development and testing of all LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHOD and the obtaining of necessary governmental approvals, if any, for marketing in the United States. These progress reports will be made for all development activities until the first SALE occurs in the United States.
Appears in 1 contract
Samples: Ambrx Biopharma Inc.
PROGRESS AND ROYALTY REPORTS. 8.1 For the period beginning [date] May 1, 2021 LICENSEE will submit to REGENTS a semi-an annual progress report covering LICENSEE's activities related to the development and testing of all LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHOD and the obtaining of necessary governmental approvals, if any, for marketing in the United States. These progress reports will be made for all development activities until the first SALE occurs in the United States.
Appears in 1 contract
Samples: Exclusive License Agreement (Kiora Pharmaceuticals Inc)
PROGRESS AND ROYALTY REPORTS. 8.1 For the period beginning [date] March 31, 2012, LICENSEE will submit to REGENTS a semi-annual progress report covering LICENSEE's ’s activities related to the development and testing of all LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHOD and the obtaining of necessary governmental approvals, if any, for marketing in the United States. These progress reports will be made for all development activities until the first SALE occurs in the United States.
Appears in 1 contract
PROGRESS AND ROYALTY REPORTS. 8.1 For the period beginning [date] October 30, 2013, LICENSEE will submit to REGENTS a semi-semi annual progress report covering LICENSEE's ’s activities related to the development and testing of all LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHOD and the obtaining of necessary governmental approvals, if any, for marketing in the United States. These progress reports will be made for all development activities until the first FIRST COMMERCIAL SALE occurs in the United States.
Appears in 1 contract
Samples: Exclusive License and Bailment Agreement (Adverum Biotechnologies, Inc.)
